Progress in Understanding the IL-6/STAT3 Pathway in Colorectal Cancer.

IL-6/STAT3 pathway colorectal cancer tumor development

Journal

OncoTargets and therapy
ISSN: 1178-6930
Titre abrégé: Onco Targets Ther
Pays: New Zealand
ID NLM: 101514322

Informations de publication

Date de publication:
2020
Historique:
received: 20 08 2020
accepted: 01 12 2020
entrez: 30 12 2020
pubmed: 31 12 2020
medline: 31 12 2020
Statut: epublish

Résumé

As a pleiotropic cytokine, interleukin-6 (IL-6) not only regulates the cellular immune response, but it also promotes tumor development by activating multiple carcinogenic pathways. IL-6 expression is significantly elevated in colorectal cancer (CRC) and is closely related to CRC development and patient prognosis. In CRC, IL-6 activates signal transducers and activators of transduction-3 (STAT3) to promote tumor initiation and tumor growth. IL-6/STAT3 signalling has a profound effect on tumor-infiltrating immune cells in the tumor immune microenvironment in CRC. Additionally, IL-6/STAT3 pathway activates downstream target genes to protect tumor cells from apoptosis; drive tumor cell proliferation, cell cycle progression, invasion and metastasis; promote tumor angiogenesis; and stimulate drug resistance. Therefore, a thorough understanding of the many effects of the IL-6/STAT3 pathway in CRC is needed, which the present review examines.

Identifiants

pubmed: 33376351
doi: 10.2147/OTT.S278013
pii: 278013
pmc: PMC7762435
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

13023-13032

Informations de copyright

© 2020 Lin et al.

Déclaration de conflit d'intérêts

The authors declare that they have no competing interests.

Références

J Clin Invest. 2015 Mar 2;125(3):1362
pubmed: 25729853
Int J Mol Sci. 2018 Mar 03;19(3):
pubmed: 29510522
Int J Cancer. 2016 Apr 15;138(8):1971-81
pubmed: 26595254
Cancer Treat Rev. 2009 Nov;35(7):553-62
pubmed: 19559538
Int J Mol Sci. 2018 Nov 09;19(11):
pubmed: 30423923
PLoS One. 2014 Apr 11;9(4):e94508
pubmed: 24728073
Mol Cancer. 2019 Mar 30;18(1):64
pubmed: 30927925
J Exp Med. 2010 Dec 20;207(13):2855-68
pubmed: 21098094
Cell Physiol Biochem. 2018;45(1):356-365
pubmed: 29402795
Oncology. 1996 Nov-Dec;53(6):448-54
pubmed: 8960139
Technol Cancer Res Treat. 2017 Dec;16(6):1209-1219
pubmed: 29333928
Arch Pharm Res. 2019 Jul;42(7):549-559
pubmed: 30941641
Biochem Biophys Res Commun. 2017 Mar 18;484(4):808-812
pubmed: 28159554
Oncogene. 2019 Mar;38(10):1676-1687
pubmed: 30348989
Cell Cycle. 2005 Feb;4(2):217-20
pubmed: 15655344
World J Clin Oncol. 2011 Jun 10;2(6):272-80
pubmed: 21773077
Int J Cancer. 2007 Dec 1;121(11):2443-50
pubmed: 17657737
Cold Spring Harb Perspect Biol. 2018 Aug 1;10(8):
pubmed: 28778870
Int J Cancer. 2019 May 15;144(10):2516-2528
pubmed: 30415472
Cancer Res. 2006 Mar 1;66(5):2544-52
pubmed: 16510571
J Exp Med. 1999 Jan 4;189(1):63-73
pubmed: 9874564
PLoS One. 2013 Jun 03;8(6):e65338
pubmed: 23755220
Crit Rev Oncol Hematol. 2014 Jan;89(1):129-39
pubmed: 24029605
Biochem Soc Trans. 2018 Dec 17;46(6):1449-1462
pubmed: 30467123
Rejuvenation Res. 2019 Apr;22(2):138-145
pubmed: 29932015
Oncotarget. 2015 Jun 10;6(16):14026-32
pubmed: 26091352
Cell Signal. 2015 Feb;27(2):293-305
pubmed: 25446253
Lancet. 2013 Jan 26;381(9863):303-12
pubmed: 23177514
Clin Sci (Lond). 2012 Feb;122(4):143-59
pubmed: 22029668
Int Immunol. 2010 May;22(5):347-52
pubmed: 20410258
Cytokine. 2016 Mar;79:82-9
pubmed: 26775116
Cancers (Basel). 2019 Oct 29;11(11):
pubmed: 31671769
Clin Cancer Res. 2014 Apr 15;20(8):2192-204
pubmed: 24563479
Oncogene. 2002 Mar 27;21(13):2000-8
pubmed: 11960372
Ther Adv Hematol. 2016 Dec;7(6):360-366
pubmed: 27904739
Int J Colorectal Dis. 2011 Jan;26(1):13-22
pubmed: 20886344
J Biol Chem. 2018 May 4;293(18):6762-6775
pubmed: 29559558
Saudi J Gastroenterol. 2011 May-Jun;17(3):170-3
pubmed: 21546718
Int J Cancer. 2014 Feb 15;134(4):997-1007
pubmed: 23934972
Cytokine. 2019 Feb;114:1-5
pubmed: 30557809
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2059-2070
pubmed: 28705384
Cancer Lett. 2006 Nov 28;244(1):76-8
pubmed: 16442710
Carcinogenesis. 2015 Apr;36(4):459-68
pubmed: 25750173
Int J Oncol. 2017 Mar;50(3):753-767
pubmed: 28098855
Int J Biol Sci. 2012;8(9):1248-53
pubmed: 23136553
Chin J Cancer Res. 2019 Jun;31(3):489-498
pubmed: 31354218
Nat Rev Clin Oncol. 2018 Apr;15(4):234-248
pubmed: 29405201
Nat Rev Gastroenterol Hepatol. 2019 Dec;16(12):713-732
pubmed: 31455888
J Agric Food Chem. 2018 May 2;66(17):4384-4393
pubmed: 29656647
Blood. 2003 Jul 1;102(1):344-52
pubmed: 12637318
Mol Ther. 2019 Oct 2;27(10):1810-1824
pubmed: 31208913
Surg Today. 2017 Apr;47(4):483-489
pubmed: 27549777
Oncotarget. 2015 Dec 22;6(41):43146-61
pubmed: 26646695
Endocrinology. 2004 Dec;145(12):5439-47
pubmed: 15331580
Oxid Med Cell Longev. 2020 Aug 13;2020:8032187
pubmed: 32855767
Science. 1993 Jun 18;260(5115):1808-10
pubmed: 8511589
Cell. 2012 Mar 30;149(1):22-35
pubmed: 22464321
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
J Surg Oncol. 2003 Aug;83(4):222-6
pubmed: 12884234
Gut. 2020 Jul;69(7):1269-1282
pubmed: 31685519
PLoS One. 2015 Oct 01;10(10):e0139727
pubmed: 26426996
Neoplasia. 2008 Mar;10(3):287-97
pubmed: 18320073
Mol Biol Rep. 2014 Jan;41(1):233-40
pubmed: 24197699
Angiogenesis. 2020 May;23(2):159-177
pubmed: 31667643
World J Gastroenterol. 2020 Apr 28;26(16):1912-1925
pubmed: 32390702
J Natl Cancer Inst. 2011 Apr 20;103(8):689-97
pubmed: 21421861
Semin Immunol. 2014 Feb;26(1):75-9
pubmed: 24447345
Trends Immunol. 2015 Feb;36(2):92-101
pubmed: 25616716
Cancer Res. 2005 Oct 1;65(19):8809-17
pubmed: 16204051
J Exp Clin Cancer Res. 2019 Jul 19;38(1):320
pubmed: 31324203
Cancer Lett. 2019 Aug 28;458:123-135
pubmed: 31121212
Nature. 2012 Jul 18;487(7407):330-7
pubmed: 22810696
Cancer Med. 2018 Nov;7(11):5382-5393
pubmed: 30123970
BMC Cancer. 2012 Sep 21;12:418
pubmed: 22994684
Mol Oncol. 2015 Jun;9(6):1194-206
pubmed: 25777967
EBioMedicine. 2019 Oct;48:648-655
pubmed: 31631043
J Cell Sci. 2019 Apr 4;132(7):
pubmed: 30948431
World J Gastroenterol. 2005 Mar 21;11(11):1639-43
pubmed: 15786541
Cancer Commun (Lond). 2019 Apr 29;39(1):22
pubmed: 31030667
Cancer Res Treat. 2015 Oct;47(4):607-15
pubmed: 25715763
Eur J Pharmacol. 2020 Oct 15;885:173505
pubmed: 32861662
BMC Cancer. 2015 Dec 16;15:975
pubmed: 26673628
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Inflamm Bowel Dis. 2015 Feb;21(2):409-18
pubmed: 25563695
World J Gastroenterol. 2017 Mar 14;23(10):1780-1786
pubmed: 28348483
Toxicol Pathol. 2010 Jan;38(1):76-87
pubmed: 20019355
Sci Rep. 2017 Mar 09;7:44053
pubmed: 28276471
Genes Dev. 2000 Dec 15;14(24):3102-14
pubmed: 11124803
Int J Oncol. 2014 Apr;44(4):1032-40
pubmed: 24430672

Auteurs

Yan Lin (Y)

Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, People's Republic of China.

Ziqin He (Z)

Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, People's Republic of China.

Jiazhou Ye (J)

Department of Hepatobiliary Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, People's Republic of China.

Ziyu Liu (Z)

Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, People's Republic of China.

Xiaomin She (X)

Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, People's Republic of China.

Xing Gao (X)

Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, People's Republic of China.

Rong Liang (R)

Department of Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi 530021, People's Republic of China.

Classifications MeSH